Navigation Links
Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
Date:9/30/2013

SAN FRANCISCO, Sept. 30, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) reported today that AstraZeneca announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for Naloxegol, an investigational peripherally-acting mu-opioid receptor antagonist, which has been specifically designed for the treatment of opioid-induced constipation (OIC) for adult patients 18 years and older, including patients with inadequate response to laxatives.

The MAA filing was based on comprehensive data from the core Phase III KODIAC programme, comprised of four clinical trials designed to investigate the safety and efficacy of naloxegol for the treatment of OIC. Two pivotal Phase III studies, KODIAC-04 (n=652) and KODIAC-05 (n=700), both 12-week, multicentre, randomised, double blind, placebo-controlled pivotal trials evaluated 12.5 mg and 25 mg doses of naloxegol, administered once-daily. KODIAC-07 was a 12-week safety extension of KODIAC-04, and KODIAC-08 (n= 534) was an open-label, randomised, 52-week, long-term safety trial.

Naloxegol has the potential to be the first once-daily oral peripherally-acting mu-opioid receptor antagonist medication for patients with OIC. Naloxegol was developed using Nektar's oral small molecule polymer conjugate technology.

Naloxegol is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics. Under the terms of the recently amended License Agreement, AstraZeneca will pay Nektar a $25 million milestone within five business days of acceptance of the MAA by the EMA.

NOTES TO EDITORS

About Opioid-Induced Constipation
OIC is a condition caused by prescription opioid pain medicines. Opioids bind to specific proteins called opioid receptors. When the opioids bind to certain opioi
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
2. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
3. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
4. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
5. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
6. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
9. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
10. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
11. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... NEW YORK, Aug. 31 Reportlinker.com announces that a ... The Market for Medical Devices in ... http://www.reportlinker.com/p0285742/The-Market-for-Medical-Devices-in-Brazil-Russia-India--China.html Many are concerned that the ... the BRIC countries. Is this a time of exciting ...
... YORK, Aug. 31 /PRNewswire/ Reportlinker.com announces that a ... catalogue: Hormone Replacement Therapy in ... 2017 http://www.reportlinker.com/p0254468/Hormone-Replacement-Therapy-in-Menopause---Pipeline-Assessment-and-Market-Forecasts-to-2017.html ... Assessment and Market Forecasts to 2017 ...
Cached Medicine Technology:Reportlinker Adds The Market for Medical Devices in Brazil, Russia, India & China 2Reportlinker Adds The Market for Medical Devices in Brazil, Russia, India & China 3Reportlinker Adds The Market for Medical Devices in Brazil, Russia, India & China 4Reportlinker Adds The Market for Medical Devices in Brazil, Russia, India & China 5Reportlinker Adds The Market for Medical Devices in Brazil, Russia, India & China 6Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 8
(Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
(Date:4/22/2014)... the United States with 1 million participants annually. A ... Injury Research and Policy at Nationwide Children,s Hospital is ... distribution patterns of basketball-related injuries treated in emergency departments ... and teens. , The study, published online in the ... to adolescents 13-19 years of age who were treated ...
(Date:4/22/2014)... 2014 Researchers at UT Southwestern Medical Center are ... depression . , A team of physician-scientists at ... ghrelin (a hormone with natural anti-depressant properties) works inside ... new treatment for depression in the form of a ... study, published online in April,s issue of Molecular ...
(Date:4/22/2014)... mice and rabbits, Johns Hopkins scientists have found a ... successfully preventing the development of atherosclerosis, the main cause ... of death among humans. The condition develops when fat ... stiff, narrowed and hardened, greatly reducing their ability to ... brain. , In a series of experiments, described April ...
(Date:4/22/2014)... LAKE CITY)A computational tool developed at the University of ... unknown gene mutations in three separate cases, U of ... study in The American Journal of Human Genetics ... tool), identifies undiagnosed illnesses and unknown gene mutations by ... that code for genes are made, in individual patients ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3
... The Company,s Commitment to Healthy and Successful Vascular ... Lifeline Vascular Access(SM), the nation,s leading provider ... its network of managed vascular access centers has ... with the Lifeline Vascular Access managed center Nephrology ...
... their full range of 7Fr IAB catheters and immediate release in the ... ... Insightra Medical Inc. , a privately held medical device company based in ... sizes including: 40cc, 35cc, 30cc, 25cc and 20cc, all in a true ...
... bleeding inside the heart after people have suffered a heart ... published today in the journal Radiology . , The ... damaged a person,s heart is after a heart attack. The ... London, hope that this kind of imaging will be used ...
... Boston, MA A collection of hospitals in eight cities ... a simple surgical checklist during major operations can lower the ... The year-long study was led by researchers from the Harvard ... Health Organization, and the results are published Online First on ...
... during breast-feeding, but resistant disease can develop in first ... -- The antiretroviral drug nevirapine may help prevent babies ... but it also greatly increases the odds of developing ... year of life, a new study finds. , Still, ...
... company, Oral BioTech, is embracing this new research on xylitol with ... Part of the motivation for these products has been the relative ... products. , ... Albany, OR (PRWEB) January 18, 2009 ...
Cached Medicine News:Health News:Lifeline Vascular Access Treats a Quarter Million Patients 2Health News:Lifeline Vascular Access Treats a Quarter Million Patients 3Health News:Insightra Medical, Inc. Gains FDA clearance for the Most Complete Range of 7Fr Intra Aortic Balloon (IAB) Catheters 2Health News:Insightra Medical, Inc. Gains FDA clearance for the Most Complete Range of 7Fr Intra Aortic Balloon (IAB) Catheters 3Health News:Bleeding hearts revealed with new scan 2Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 2Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 3Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 4Health News:HIV Drug a Double-Edged Sword for Infants 2Health News:Keeping Kids Cavity-Free Before They're Ever Born: CariFree Believes Xylitol Could be This Generation's Answer 2Health News:Keeping Kids Cavity-Free Before They're Ever Born: CariFree Believes Xylitol Could be This Generation's Answer 3
Straight shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide serrated handle with polished finish....
Serrated, 10 mm tips angled 30 degrees. Serrated cross action handle with polished finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide smooth handle with polished finish....
Medicine Products: